Get the Stockscreener App
76.20
0.46%
-0.35
Tarsus Pharmaceuticals Inc stock is traded at $76.20, with a volume of 262.87K.
It is down -0.46% in the last 24 hours and up +19.98% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
See More
Previous Close:
$76.55
Open:
$76.67
24h Volume:
262.87K
Relative Volume:
0.45
Market Cap:
$3.24B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-16.42
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+4.89%
1M Performance:
+19.98%
6M Performance:
+32.68%
1Y Performance:
+71.24%
1-Day Range:
$75.86
$78.20
1-Week Range:
$71.97
$78.20
52-Week Range:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
76.20 | 3.26B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Vanguard Group Inc. - MarketBeat
Tarsus Pharmaceuticals at TD Cowen Conference: Eyeing Blockbuster Growth By Investing.com - Investing.com Canada
TARS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A Look At Tarsus Pharmaceuticals (TARS) Valuation After 2025 Results And New Shelf Registration - Sahm
Tarsus Pharmaceuticals (TARS) Stock Analysis: Strong Buy Ratings and 21.88% Upside Potential - DirectorsTalk Interviews
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen - ChartMill
Aug PreEarnings: Why is Oak Woods Acquisition Corporation Equity Right stock going upWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Boosts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
(TARS) Risk Channels and Responsive Allocation - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Stream Tarsus Pharma at TD Cowen and Barclays investor events in March - Stock Titan
HC Wainwright Brokers Decrease Earnings Estimates for TARS - MarketBeat
Tarsus Pharmaceuticals (TARS) Is Up 14.8% After XDEMVY-Fueled Revenue Surge and New Equity Shelf Filing - simplywall.st
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Receives Analyst Rating Upgrade fr - GuruFocus
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $105.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $90.00 at Guggenheim - MarketBeat
TARS: Guggenheim Raises Price Target to $90, Maintains Buy Ratin - GuruFocus
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating - marketscreener.com
Analysts Offer Predictions for TARS FY2030 Earnings - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Healthcare Innovator with 32.92% Potential Upside - DirectorsTalk Interviews
Tarsus Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Narrowing EPS Loss Backs Bullish Earnings Turnaround Narrative - simplywall.st
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap UpTime to Buy? - MarketBeat
Tarsus Pharmaceuticals (TARS) Shares Surge Over 11% - GuruFocus
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights - Intellectia AI
Tarsus Pharma's XDEMVY Sales Soar 150% In FY25, Peak Sales Potential To Exceed $2Bln - RTTNews
Tarsus Pharmaceuticals, Inc. (TARS) reports Q4 loss, beats revenue estimates - MSN
Decoding Tarsus Pharmaceuticals Inc (TARS): A Strategic SWOT Ins - GuruFocus
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Tarsus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
TARS: 2026 sales guidance set at $670–$700M, with XDEMVY on track for $2B+ US peak sales - TradingView
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen - ChartMill
Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth - Investing.com
Tarsus Pharmaceuticals Adds David Pyott, Boosts Leadership with Allergan Experience - timothysykes.com
Tarsus Pharmaceuticals Q4 Loss Shrinks, Revenue Rise - marketscreener.com
Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q4 Loss $0.20, vs. Loss of $0.60 a Year Ago - marketscreener.com
Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q4 Revenue $151.7M, vs. FactSet Est of $144.6M - marketscreener.com
Tarsus Pharmaceuticals Reports $451.4 Million in XDEMVY® Sales for Full-Year 2025 and Announces New Clinical Trials for Ocular Rosacea and Lyme Disease Prevention - Quiver Quantitative
Tarsus Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Insights into Tarsus Pharmaceuticals Q4 Earnings - Benzinga
BRIEF-Tarsus Pharmaceuticals Q4 EPS USD -0.2 - TradingView
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements - GlobeNewswire
A Look At Tarsus Pharmaceuticals (TARS) Valuation After David Pyott Joins The Board - Sahm
Will Tarsus Pharmaceuticals Inc. stock recover after earnings2025 Technical Patterns & Daily Growth Stock Investment Tips - mfd.ru
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):